NeoManna creates innovative antimicrobial and anti-inflammatory products for animal health markets, starting with Black Soldier Fly produced ingredients and expanding to other sources. Their solutions enhance weight gain, improve feed conversion ratios, and reduce mortality, significantly boosting producers' ROI across companion animals, aquaculture, ruminants, and monogastrics.
Located: Israel
Seeking: USD 4 million
Overuse of antimicrobials accelerates microbial resistance, threatening humans, animals, and crops. Regulatory and consumer-driven bans on antimicrobials as growth promoters increase production costs, raising prices of broiler, swine, and fish meat, jeopardizing global food security and value chains.
Utilizing BSF-derived ingredients, NeoManna promotes environmentally friendly practices in animal health, catering to the growing demand for natural products.
The addressable anti-microbial animal health market, spanning pet healthcare, feed additives, farm animal drugs, and aquaculture therapeutics, is poised for significant growth. Valued at $63.3 billion in 2023, it is projected to reach $119.34 billion by 2032, driven by rising demand for sustainable solutions to combat antimicrobial resistance and enhance animal health and productivity across diverse sectors..
NeoManna products and product combinations, are aimed at breaking the current production performance and profitability “ceilings” of aquaculture and livestock.
NeoMAG and NeoPRO are cutting-edge solutions leveraging Black Soldier Fly (BSF) bioactives. NeoMAG delivers potent antimicrobial effects, targeting Gram-positive/negative bacteria, viruses, and Coccidia. NeoPRO offers effective anti-inflammatory benefits by reducing cytokines, rivaling prescription products.
NeoManna's advanced labs drive innovation with BSF colony lifecycle management, robust bioinformatics, and state-of-the-art facilities, ensuring scalable, precision-driven solutions for animal health and crop development.
NeoManna scales antimicrobial and anti-inflammatory products via strategic sourcing, local distribution, tier-1 manufacturing, and science-driven demand generation. Their go-to-market strategy focuses on B2B2C positioning for high-ROI animal health products, leveraging local distributors, strategic raw material sourcing with feed company, tier-1 contract manufacturing in France and Greece, and science-driven demand through KOL-backed trials and field experiments
A highly skilled, multi-disciplinary team of 10 professionals drives research and development, ensuring market-aligned innovations. Expertise spans Agbiotech, foodtech, supply chain optimization, and biochemistry, with leadership experienced in entrepreneurship, product development, and commercialization. The team excels in scaling biological solutions and pioneering advancements in sustainable agriculture and animal health.
